Teva Pharmaceutical Industries Limited (NYSE:TEVA) Vice Chairman David Matthew Stark Sells 58,163 Shares

Teva Pharmaceutical Industries Limited (NYSE: TEVA – Get a rating) VP David Matthew Stark sold 58,163 shares of Teva Pharmaceutical Industries in a trade that took place on Thursday, July 28. The stock was sold at an average price of $9.04, for a total value of $525,793.52. Following the completion of the sale, the vice president now directly owns 2,974 shares of the company, valued at $26,884.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available via this hyperlink.

Price performance of Teva Pharmaceutical Industries

Shares of TEVA opened at $9.45 on Friday. The company has a 50-day simple moving average of $8.02 and a two-hundred-day simple moving average of $8.39. The company has a debt ratio of 2.03, a current ratio of 1.07 and a quick ratio of 0.73. Teva Pharmaceutical Industries Limited has a 1-year low of $6.78 and a 1-year high of $10.50. The stock has a market capitalization of $10.43 billion, a PE ratio of -17.18, a P/E/G ratio of 0.91 and a beta of 1.22.

Teva Pharmaceutical Industries (NYSE:TEVA- Get a rating) last reported results on Tuesday, May 3. The company reported earnings per share of $0.53 for the quarter, matching the consensus estimate of $0.53. Teva Pharmaceutical Industries recorded a negative net margin of 3.95% and a positive return on equity of 24.04%. The company posted revenue of $3.66 billion in the quarter, versus a consensus estimate of $3.75 billion. In the same quarter last year, the company achieved EPS of $0.60. The company’s revenue for the quarter was down 8.1% year over year. As a group, analysts expect Teva Pharmaceutical Industries Limited to post EPS of 2.37 for the current year.

Wall Street analysts predict growth

A number of research analysts have weighed in on the company. Piper Sandler downgraded Teva Pharmaceutical Industries from a “neutral” rating to an “underweight” rating and lowered its price target for the company from $11.00 to $7.00 in a Wednesday, May 4, report. UBS Group took over coverage of Teva Pharmaceutical Industries shares in a Monday, June 13 research report. They set a “neutral” rating and a price target of $10.00 on the stock. StockNews.com moved shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a Friday, June 17 research note. Bank of America upgraded Teva Pharmaceutical Industries from an “underperforming” rating to a “neutral” rating and set a price target of $9.00 for the company in a Tuesday, May 17 research report. Finally, Barclays upgraded Teva Pharmaceutical Industries from an “equal weight” rating to an “overweight” rating and raised its price target for the stock from $11.00 to $13.00 in a research report Tuesday, April 5. One research analyst rated the stock with a sell rating, five gave a hold rating and three issued a buy rating for the company’s shares. According to data from MarketBeat.com, Teva Pharmaceutical Industries has an average rating of “Hold” and an average target price of $10.71.

Institutional investors weigh in on Teva Pharmaceutical Industries

Several institutional investors and hedge funds have recently changed their holdings in the company. Ensign Peak Advisors Inc increased its stake in Teva Pharmaceutical Industries by 3.4% during the 4th quarter. Ensign Peak Advisors Inc now owns 45,850 shares of the company valued at $367,000 after acquiring an additional 1,500 shares during the period. Straight Path Wealth Management increased its position in shares of Teva Pharmaceutical Industries by 17.9% during the first quarter. Straight Path Wealth Management now owns 66,000 shares of the company worth $620,000 after purchasing an additional 10,000 shares in the last quarter. Nisa Investment Advisors LLC bought a new position in shares of Teva Pharmaceutical Industries in the fourth quarter worth approximately $794,000. Davy Global Fund Management Ltd increased its holdings of Teva Pharmaceutical Industries shares by 10.0% in the fourth quarter. Davy Global Fund Management Ltd now owns 141,219 shares in the company valued at $1,131,000 after buying an additional 12,889 shares in the last quarter. Finally, Factorial Partners LLC increased its stake in Teva Pharmaceutical Industries by 71.6% during the 1st quarter. Factorial Partners LLC now owns 151,000 shares of the company worth $1,418,000 after purchasing an additional 63,000 shares during the period. Hedge funds and other institutional investors own 45.79% of the company’s shares.

Teva Pharmaceutical Industries Company Profile

(Get a rating)

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets and distributes generic drugs, specialty drugs and biopharmaceuticals in North America, Europe and internationally. The company offers sterile products, hormones, high potency drugs and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments and creams.

Further reading

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Teva Pharmaceutical Industries right now?

Before you consider Teva Pharmaceutical Industries, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Teva Pharmaceutical Industries was not on the list.

Although Teva Pharmaceutical Industries currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here